FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/26/2023
Back to search
Official data from USPTO
MNEMO THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079330694Class
1, 5, 10, 40, 42, 44
Filing
79330694
Registration
7152728
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
12/26/2023
Trademark type
Combined
Nice classes
1, 5, 10, 40, 42, 44
Filing date
09/14/2021
Registration date
09/05/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/05/2023
Last transaction
09/05/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
FR
Examiner
CHANG, BETTY
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a hummingbird design in the colors purple, blue, green and yellow and the stacked wordings "MNEMO" in purple and "THERAPEUTICS" in green.
Holders and representatives
Holders
M. T. (pessoa física)
Representatives
Jill Anderfuren Lewis Brisbois Bisgaard & Smith LLP
Technical classification
Nice Classes
Class 1Class 5Class 10Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological and chemical products for manufacturing and research use in the pharmaceutical industry; chemical reagents for the manufacture of therapeutic immunotherapy solutions
Class 5
Pharmaceutical products for use in oncology and immunotherapy; biological and pharmaceutical preparations for treatment of cancer and tumors; biological and pharmaceutical preparations for the treatment of cancer and tumors using immunotherapy; therapeutic preparations being solutionsantigenantibodiesT-cells in the nature of preparations for treatment of cancer and tumors; biological materialspreparationsreagents being pharmaceutical for products for medical use in the treatment of cancer and tumors; antigensantibodiescells for therapeutic use
Class 10
apparatus and instruments for carrying out tests and diagnostics for medical usemedical imagingbiopsiesgenetic and molecular analysis ; medical apparatus and instruments for identifyingscreeninganalyzing antigens for medical use; medical apparatus for reading of analytical testsnamely molecularblood and genetic testing
Class 40
Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; Custom manufacturing of antigensantibodiesT-cells; Providing manufacturing information in the field of pharmaceuticals
Class 42
Scientific research services for medical purposesmedical research; Scientific research and development services for identifyingscreening and developing antigens; scientific and technological servicesscientific researchanalysis and testing in the field of oncology and immunotherapy; scientific laboratory services; providing scientific information with regard to immunotherapy; Scientific research and development servicesproviding services for the identificationanalysisauthenticationpurification and development of biological material from a genomic platform; Scientific researchepigenetic antigen identification and screening services for therapeutic research purposes; Scientific researchgenomic and epigenetic characterization services for identifying drug candidates in immunotherapy; Scientific and medical research servicesdesigning algorithms and models for use in scientific and medical research; Providing temporary use of online non-downloadable computer software platforms featuring algorithms for analyzing cellsantigenstissuesgene expressionsgene sequencesgenome annotationsantigen characteristics and immunological responses; Providing temporary use of an online non-downloadable computer software platform featuring algorithms for predicting the characteristics of antigens and immunological responses
Class 44
Providing medical information with regard to immunotherapy
Publications
History of USPTO decisions and trademark events.
47 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/06/2023
FIMP
FINAL DISPOSITION PROCESSED
12/06/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/05/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
09/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/20/2023
PUBO
PUBLISHED FOR OPPOSITION
06/20/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/19/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/31/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/31/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/31/2023
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
05/02/2023
RFNP
REFUSAL PROCESSED BY IB
04/19/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/14/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/16/2023
GNRT
NON-FINAL ACTION E-MAILED
03/16/2023
CNRT
NON-FINAL ACTION WRITTEN
03/16/2023
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
03/16/2023
RINX
USPTO CORRECTION PROCESSED BY IB
03/05/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/05/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/01/2023
GNFR
FINAL REFUSAL E-MAILED
02/01/2023
CNFR
FINAL REFUSAL WRITTEN
02/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/31/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/30/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/30/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/30/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/30/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/30/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/30/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/30/2023
CRSN
CORRECTION SENT TO IB
12/12/2022
CRCR
CORRECTION CREATED FOR IB
12/07/2022
RFNT
REFUSAL PROCESSED BY IB
08/23/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/29/2022
RFRR
REFUSAL PROCESSED BY MPU
07/29/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/06/2022
CNRT
NON-FINAL ACTION WRITTEN
07/05/2022
DOCK
ASSIGNED TO EXAMINER
06/17/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/07/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/06/2022
Continuous trademark protection
Get notified about every new filing that threatens MNEMO THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.